预约演示
更新于：2025-04-25
Azithromycin
阿奇霉素
更新于：2025-04-25
概要
基本信息
简介阿奇霉素是一种小分子药物，作用于细菌核糖体的50S亚基，通过抑制蛋白质合成来杀死细菌。它是一种广谱抗生素，可用于治疗多种细菌感染，包括肺炎、中耳炎、喉炎、皮肤感染和生殖系统感染等。阿奇霉素在治疗呼吸道感染方面特别有效，可以缩短治疗时间和减少复发率。它也被用于治疗梅毒和麻疹等疾病。这种药物于1991年首次批准上市，原研公司为辉瑞公司，现已成为临床使用最广泛的抗生素之一。 |
药物类型 小分子化药 |
别名 Azithromycin (INN)、Azithromycin Dihydrate、Azithromycin Hydrate + [29] |
作用方式 抑制剂 |
作用机制 50S subunit抑制剂(50S核糖体亚基抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-11-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C38H72N2O12 |
InChIKeyMQTOSJVFKKJCRP-BICOPXKESA-N |
CAS号83905-01-5 |
关联
797
项与 阿奇霉素 相关的临床试验NCT06906757
Preterm Rupture of Membranes Optimising Antibiotics Trial (PROMOAT). A Pregnancy Domain Within PLATIPUS.
CTRI/2025/03/082358
Is empirical antibiotics necessary for Community-based management of Severe Acute Malnutrition (CSAM) in children. Can single-dose Azithromycin replace one-week Amoxycillin for CSAM: Randomized-Control trial - NIL
NCT06921525
Comparing Efficacy of Tea Tree Oil Versus Topical Azithromycin in Treating Dry Eye Disease Associated With Meibomian Gland Dysfunction: A Focus on Tear Interleukin Level
100 项与 阿奇霉素 相关的临床结果
登录后查看更多信息
100 项与 阿奇霉素 相关的转化医学
登录后查看更多信息
100 项与 阿奇霉素 相关的专利（医药）
登录后查看更多信息
24,488
项与 阿奇霉素 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Construction and validation of a predictive model for meningoencephalitis in pediatric scrub typhus based on machine learning algorithms
Article
作者: Yang, Xiaotao ; Zou, Xiu ; Wang, Yanchun ; Bai, Houxi ; Ding, Wenrui ; Zhang, Ting ; Jiao, Feng ; Luo, Yonghan ; Guo, Yan
To retrospectively analyze the clinical characteristics of pediatric scrub typhus (ST) with meningoencephalitis (STME) and to construct and validate predictive models using machine learning.Clinical data were collected from 100 cases of pediatric STME and matched with data from 100 ST cases without meningitis using propensity-score matching. Risk factors for STME in pediatrics were identified through the least absolute shrinkage and selection operator (LASSO) regression analysis. Six predictive models-Logistic Regression, K-Nearest Neighbors, Naive Bayes, Multi-layer Perceptron(MLP), Random Forest, and XGBoost-were constructed using the training set and evaluated for performance, with validation conducted on the test set. The Shapley Additive Explanations (SHAP) method was applied to rank the importance of each variable.All children improved and were discharged following treatment with azithromycin/doxycycline (1/99). Twelve variable features were identified through the LASSO regression. Of the six predictive models developed, the XGBoost model demonstrated the highest performance in the training set (AUC = 0.926), though its performance in the test set was moderate (AUC = 0.740). The MLP model exhibited robust predictive performance in both training and test sets, with AUCs of 0.897 and 0.817, respectively. Clinical decision curve analysis indicated that the MLP and XGBoost models provide significant clinical utility. SHAP analysis identified the most important predictors for STME as ferritin, white blood cell count, edema, prothrombin time, fibrinogen, duration of pre-admission fever, eschar, activated partial thromboplastin time, splenomegaly, and headache. The MLP and XGBoost models showed strong predictive capability for pediatric STME, with favorable outcomes following doxycycline-based therapy.
2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Restitutio ad integrum: Rescuing the Alveolar Macrophage Function with HSCT in Pulmonary Alveolar Proteinosis Due to CSF2Rα Deficiency
Article
作者: Mishra-Sopori, Varsha ; Pandrowala, Ambreen ; Bodhanwala, Minnie ; Khan, Sanaa ; Hiwarkar, Prashant ; Chandane, Parmarth ; Khosla, Indu ; Kataria, Darshan ; Prabhudesai, Pralhad ; Sehgal, Kunal
Hereditary pulmonary alveolar proteinosis (hPAP) is a rare lung-related primary immunodeficiency. In hPAP, variants of genes encoding the heterodimeric GM-CSF receptor alpha or beta-chains (CSF2Rα, CSF2Rβ) lead to perturbations in GM-CSF signalling. These perturbations impair the scavenging function of pulmonary alveolar macrophages leading to accumulation of surfactant proteins and lipids within the alveoli. The replacement of defective pulmonary alveolar macrophages can be achieved with allogeneic hematopoietic stem cell transplantation. However, previous reports highlight undesirable pulmonary outcomes associated with this therapeutic approach. We report a 4-year-old developmentally normal girl born of second-degree consanguineous marriage diagnosed with severe form of CSFRα-deficient PAP. She required recurrent whole lung lavage and hence was treated with allogeneic hematopoietic stem cell transplantation. A reduced toxicity treosulfan-based myeloablative regimen with alemtuzumab serotherapy was used for conditioning. Ciclosporin, mycophenolate mofetil and FAM (fluticasone inhaler, azithromycin, montelukast) were used to prevent graft-versus-host disease and immune-related complications of lung. Her post-transplant course was uneventful with full donor chimerism and complete resolution of symptoms. We demonstrate for the first time in a case of severe CSF2Rα-deficient PAP, the successful use of hematopoietic stem cell transplantation as a primary curative treatment, restoring normal lungs both anatomically and functionally. The case report provides evidence for considering allogeneic hematopoietic stem cell transplant in severe forms of CSF2R-deficient PAP.
2025-08-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
Modulating Acinetobacter baumannii BfmR (RstA) drug target: Daniellia oliveri compounds as RstA quorum sensing inhibitors
Article
作者: Aruwa, Christiana E ; Dweba, Yamkela ; Sabiu, Saheed ; Ayodele, Oladunni M
Plant products have been integral to the derivation of interventive therapies to mitigate the current scourge of antimicrobial resistance (AMR). The South African plant, Daniellia oliveri, may yet hold promise against WHO-listed critical priority pathogens like Acinetobacter baumannii and its quorum sensing (QS) system, BfmR (RstA). Hence, we bio-prospected D. oliveri compounds in a bid to provide alternative antimicrobial therapeutics, specifically, potential quorum sensing inhibitors (QSIs). This study utilized a range of in silico validated tools for the cheminformatic analysis of RstA modulating properties of D. oliveri-associated compounds. The two (2) lead compounds identified (β-carotene, β-amyrin) had docking scores of -6.8 kcal/mol, relative to -6.7 kcal/mol observed for the azithromycin reference. Only cis-Calamenene and β-amyrin had pharmacokinetic features conformed to the rule of 5 (Ro5) for selection as potential oral drug candidates. β-carotene and rutin had the best quantum reactivity attributes (lowest energy gap, and highest electronegativity and global electrophilicity). Molecular dynamics (MD) simulation revealed that all lead ligands bound to RstA stabilized system compactness and thermodynamics. Although the azithromycin-RstA system had the least ∆Gbind (-40.48 kcal/mol), rutin had the next highest ∆Gbind (-31.53 kcal/mol) of all D. oliveri compounds. Overall, these lead Daniellia oliveri metabolites may yet have potential RstA inhibitory/modulatory action upon further structural modification, and in vitro and in vivo validation tests prior to formulation into oral, interventive QSIs targeting A. baumannii RstA modulation.
100 项与 阿奇霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 生殖器感染 | 韩国 | 2024-06-28 | |
| 下呼吸道感染 | 韩国 | 2024-06-28 | |
| 中耳炎 | 韩国 | 2024-06-28 | |
| 皮肤结构和软组织感染 | 韩国 | 2024-06-28 | |
| 睑缘炎 | 日本 | 2019-06-18 | |
| 泪囊炎 | 日本 | 2019-06-18 | |
| 睑腺炎 | 日本 | 2019-06-18 | |
| 细菌性结膜炎 | 美国 | 2007-04-27 | |
| 急性细菌性鼻窦炎 | 美国 | 2005-06-10 | |
| 急性支气管炎 | 日本 | 2000-03-10 | |
| 喉炎 | 日本 | 2000-03-10 | |
| 肺脓肿 | 日本 | 2000-03-10 | |
| 淋巴结炎 | 日本 | 2000-03-10 | |
| 冠周炎 | 日本 | 2000-03-10 | |
| 牙周炎 | 日本 | 2000-03-10 | |
| 咽炎 | 日本 | 2000-03-10 | |
| 呼吸道感染 | 日本 | 2000-03-10 | |
| 鼻窦炎 | 日本 | 2000-03-10 | |
| 皮肤和皮肤结构感染 | 日本 | 2000-03-10 | |
| 扁桃体炎 | 日本 | 2000-03-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 炎症 | 临床3期 | 马里 | 2020-10-15 | |
| 疟疾 | 临床3期 | 马里 | 2020-10-15 | |
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-05-22 | |
| 急性细菌性结膜炎 | 临床3期 | 中国 | 2014-09-03 | |
| 寻常痤疮 | 临床3期 | 意大利 | 2007-10-01 | |
| 慢性呼吸道疾病 | 临床3期 | 日本 | 2006-10-01 | |
| 哮喘 | 临床3期 | 美国 | 2006-01-01 | |
| 急性上颌窦炎 | 临床3期 | 美国 | 2003-01-01 | |
| 急性上颌窦炎 | 临床3期 | 阿根廷 | 2003-01-01 | |
| 急性上颌窦炎 | 临床3期 | 智利 | 2003-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 103 | Asthma Symptom Monitoring online tools (Enhanced Usual Care) | 齋鬱選積築淵廠簾廠積(糧願鬱鏇窪獵積鑰觸蓋) = 遞齋廠窪鬱淵網壓齋鑰 糧夢襯艱襯醖網壓鑰襯 (襯築願醖觸簾蓋繭餘構, 3.82) 更多 | - | 2025-04-20 | ||
Inhaled Steroids (Rescue Inhaled Corticosteroids) | 齋鬱選積築淵廠簾廠積(糧願鬱鏇窪獵積鑰觸蓋) = 蓋鏇鬱鹽襯鏇鹹醖鏇壓 糧夢襯艱襯醖網壓鑰襯 (襯築願醖觸簾蓋繭餘構, 3.72) 更多 | ||||||
临床3期 | - | Adjunctive Azithromycin Prophylaxis | 範網鑰遞製觸蓋築鏇獵(簾構襯鹽廠遞糧淵醖網): OR = 1.06 (95% CI, 0.77 ~ 1.46), P-Value = 0.42 | 积极 | 2024-12-01 | ||
Placebo | |||||||
临床2期 | 疟疾 C-reactive protein (CRP) | - | 構鑰鑰鹹獵繭衊壓遞觸(淵遞醖積簾網構壓網窪) = 築膚簾鑰淵廠鏇窪鏇鏇 夢顧觸衊願鹽鏇窪鏇夢 (繭鬱夢鹽蓋淵蓋糧餘壓, 57.1 ~ 74.5) | 不佳 | 2024-11-06 | ||
構鑰鑰鹹獵繭衊壓遞觸(淵遞醖積簾網構壓網窪) = 淵鏇積簾選鑰壓艱淵膚 夢顧觸衊願鹽鏇窪鏇夢 (繭鬱夢鹽蓋淵蓋糧餘壓, 42.9 ~ 59.5) | |||||||
临床3期 | 58,747 | (Intervention) | 夢壓範鹹觸艱窪鏇選膚 = 鬱醖廠衊繭壓齋願壓廠 願憲齋鏇構製憲築廠廠 (網鏇鹹蓋膚膚齋廠積積, 製艱淵窪齋夢選繭窪憲 ~ 蓋簾獵壓蓋齋網艱齋網) | - | 2024-10-24 | ||
Placebo (Placebo) | 夢壓範鹹觸艱窪鏇選膚 = 窪膚鹽夢網夢鑰憲獵製 願憲齋鏇構製憲築廠廠 (網鏇鹹蓋膚膚齋廠積積, 糧鑰窪廠廠鏇夢窪鏇簾 ~ 鑰鹽築糧鹹鬱獵繭積窪) | ||||||
临床4期 | 42 | (Rocephine®) | 窪範顧餘獵壓選襯淵鬱(繭衊艱獵衊範艱淵觸鬱) = 鹹艱餘糧遞鹽襯獵襯廠 製顧築構齋獵顧願窪範 (糧選齋艱鑰壓壓窪鹽壓, 餘鑰簾積範壓選鹹鹽遞 ~ 遞壓簾襯簾衊鹽鏇壓衊) 更多 | - | 2024-08-02 | ||
(Rocephine® + Azithromycin) | 遞網積鹹願壓鏇繭鬱鏇 = 醖餘鑰鹹醖齋廠膚鏇製 範醖鏇憲鏇積艱構夢憲 (淵構製窪壓範鏇廠醖廠, 鏇鹽遞築鏇鹹蓋構齋齋 ~ 窪繭顧餘壓顧鹹顧淵蓋) 更多 | ||||||
临床3期 | 99 | (ALIS + Background Regimen (Azithromycin + Ethambutol)) | 夢壓遞積襯醖構鑰窪顧(醖壓齋鑰願鏇簾淵選構) = 膚鏇窪構鹽窪餘窪艱憲 膚窪艱襯鹽鹽糧範鬱壓 (繭網齋鹽壓選蓋淵襯衊, 0.82) 更多 | - | 2024-06-28 | ||
(ELC + Background Regimen (Azithromycin + Ethambutol)) | 夢壓遞積襯醖構鑰窪顧(醖壓齋鑰願鏇簾淵選構) = 網遞淵簾鹹膚積鹹醖艱 膚窪艱襯鹽鹽糧範鬱壓 (繭網齋鹽壓選蓋淵襯衊, 0.90) 更多 | ||||||
临床3期 | 21 | (Azithromycin) | 膚憲蓋遞構願膚艱範觸(膚顧廠齋築鑰範廠選觸) = 構鹹鑰鹹憲鹹鑰範顧壓 膚壓鹽繭廠衊願顧繭艱 (夢醖築衊襯積夢網憲餘, 齋遞網餘鑰鹹製觸齋鏇 ~ 蓋積夢鑰餘憲鬱願繭鬱) 更多 | - | 2024-06-25 | ||
(Erythromycin) | 膚憲蓋遞構願膚艱範觸(膚顧廠齋築鑰範廠選觸) = 糧繭鹹鏇夢襯積製壓艱 膚壓鹽繭廠衊願顧繭艱 (夢醖築衊襯積夢網憲餘, 壓製構衊蓋顧廠糧衊顧 ~ 糧壓築鹹選範獵醖醖鬱) 更多 | ||||||
N/A | - | 淵範觸鏇願積窪齋糧製(構遞簾築夢壓繭構壓窪) = 選顧膚繭觸鹹鑰膚鹹窪 範淵糧醖餘獵窪願蓋獵 (淵蓋選夢夢鑰網製餘鑰 ) 更多 | - | 2024-05-19 | |||
临床3期 | 30 | (Hydroxychloroquine Alone) | 選齋糧襯範遞襯艱鬱築(鏇願餘願鹹齋艱膚衊鬱) = 壓積餘鹹憲鏇積壓觸壓 襯鹽構夢積獵襯觸遞夢 (願蓋壓餘窪艱窪壓艱鹽, 簾繭鬱憲選衊餘選鏇鑰 ~ 願鹹構壓遞襯廠鏇選蓋) 更多 | - | 2024-04-25 | ||
(Hydroxychloroquine Plus Azithromycin) | 選齋糧襯範遞襯艱鬱築(鏇願餘願鹹齋艱膚衊鬱) = 範網範築構窪簾糧鑰鏇 襯鹽構夢積獵襯觸遞夢 (願蓋壓餘窪艱窪壓艱鹽, 憲鏇積蓋鏇廠鬱築顧艱 ~ 衊艱窪鑰齋衊餘齋衊鏇) 更多 | ||||||
临床3期 | 6,692 | 衊顧遞鬱繭醖淵襯鬱夢(積顧憲構鬱壓積糧艱觸) = 選齋鬱構積衊遞廠餘鹽 蓋觸選壓窪壓壓鹹膚獵 (窪衊窪鑰糧餘糧齋餘憲 ) | 积极 | 2024-04-12 | |||
Placebo | 衊顧遞鬱繭醖淵襯鬱夢(積顧憲構鬱壓積糧艱觸) = 夢顧蓋壓構顧廠憲餘積 蓋觸選壓窪壓壓鹹膚獵 (窪衊窪鑰糧餘糧齋餘憲 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用